Tender detail
Medicinal Products V [2027–2029]
Summary
Masaryk Memorial Cancer Institute is procuring medicinal products in seven lots for delivery from 2027 to 2029: osimertinib, lapatinib, sotorasib, amivantamab, lazertinib, ribociclib and capivasertib. The stated estimated value, including reserved changes, is CZK 307,980,000 excluding VAT. Quantities are approximate and may vary by up to 50% in either direction; the contract period may be extended once by three months.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.